Piramal Eswasthya

In: Business and Management

Submitted By sadhu040987
Words 257
Pages 2
ANALYSIS :
Few Major flaws in the pilot programme had been due to 1. Choosing of Rajasthan as an Indian state. 2. Choosing villages as the target geography. 3. Orthodox attitude of people combined with low education.
Problem Statement: The 1 major problem had been unsustainability of the project due to insufficient generation of revenues to cover the costs. Revenues were less due to lesser than expected number of patients turning up. Low number of patients was due to a) Lower population density of Rajasthan b) Lower population density of village areas. c) Misguidance of villagers by other practitioners. d) One stop treatment was not there.

* Had higher population density states were selected like UP, Bihar or West Bengal, the turnout of patients as percentage of total population would naturally led to better revenues. * The cost of mobile van services for healthcare could also had better coverage by covering lot more patients with same number of kilometres covered. * Secondly, instead of choosing villages, suburban towns could have been selected as their also quality of healthcare is not as good and ‘jholachhaps’ are prominent. But, advantage there would have been better education of people seeking quality healthcare and higher income groups present there. * Marketing programs and efforts such as movie screening would have covered a larger number of audiences in higher population towns. * For higher population, even full time doctor could have been available full time.
By increasing the number of patients per sahayika, the cost would have been covered in efficient ways and project would be sustainable.…...

Similar Documents

Business Management

...Mistry Tata Sons 16 Sunil Bharti Mittal Bharti Enterprises 17 Naveen Jindal Jindal Steel & Power 18 Nitin Paranjpe Hindustan Unilever 19 Shiv Nadar HCL 20 Venu Srinivasan Sundaram Clayton, TVS Motor Company Rank Name Company 21 SP Hinduja Hinduja Group 22 Sajjan Jindal JSW Steel 23 Anil Agarwal Vedanta Resources 24 KP Singh DLF Group 25 Rajiv Bajaj Bajaj Auto 26 YC Deveshwar ITC 27 HM Nerurkar Tata Steel 28 S D Shibulal Infosys 29 Kiran Mazumdar Shaw, Biocon 30 Dr. K Anji Reddy Dr. Reddy's Laboratories 31 Sanjay Lalbhai Arvind 32 Nusli Wadia Wadia Group 33 Subhash Chandra Zee Group 34 Aditya Puri HDFC Bank 35 Pawan Munjal Hero Moto Corp 36 Pratip Chaudhuri State Bank of India 37 Prathap C. Reddy Apollo Hospitals Group 38 Ajay Piramal Piramal Group 39 Kalanidhi Maran Sun Group 40 G M Rao GMR Group Rank Name Company 41 N Srinivasan India Cements 42 Kishore Biyani Future Group 43 Vijay Mallya UB Group 44 TS Vijayan LIC 45 Ratan Jindal Jindal Stainless 46 R Mukundan Tata Chemicals 47 Y K Hamied Cipla 48 Sudhir Vasudeva ONGC 49 Gautam Thapar Avantha Group 50 KR Kamath Punjab National Bank 51 Prakash M Telang Tata Motors 52 Bhaskar Bhat Titan Industries 53 D Shivakumar Nokia India, Middle East & Africa 54 Pankaj Patel Cadila Healthcare 55 Shobhana Bhartia HT Media 56 Arup Roy Choudhury NTPC 57 Ramesh Chandra Agarwal Dainik Bhaskar Group 58 Shikha Sharma Axis Bank 59 Ashwin C Choksi Asian Paints 60 MD Mallya Bank of Baroda Rank Name Company 61 Uday Kotak Kotak Mahindra...

Words: 463 - Pages: 2

Indian Pharma Industry

...volume among the top 15 drug manufacturing countries.     Further, McKinsey reports Healthcare grew from 4 per cent of average household income in 1995 to 7 per cent in 2005 and is expected to grow to 13 per cent by 2025.    Diagnostics Outsourcing / Clinical Trials: According to the estimates, the Indian diagnostics and labs test services, in view of its growth potential, is expected to reach Rs159.89 billion by FY2013. The Indian market for both therapeutic and diagnostic antibodies is expected to grow exponentially in the coming years. Further, more than 60% of the total antibodies market is currently dominated by diagnostic antibodies.    Some of the major Indian pharmaceutical firms, including Sun Pharma, Cadilla Healthcare and Piramal Life Sciences, had applied for conducting clinical trials on at least 12 new drugs in 2010, indicating a growing interest in new drug discovery research.    Generics: India tops the world in exporting generic medicines worth US$ 11 billion. The Indian generic drug market is to grow at a CAGR of around 17 per cent between 2010-11 and 2012-13.   Over the next few years, it is expected that the patent laws will provide impetus to the launch of patent-protected products. Such products have the potential to capture upto a 10% share of the market by 2015, implying the market size of US $2bn.    R&D: According to Battelle R&D magazine, gross expenditure on R&D (GERD) by India for 2012 was projected to be US$ 41 billion in......

Words: 1969 - Pages: 8

Worksheet Analysis

...steroid injections   Trust and reliability of Piramal e-swasthya Confidence of people in Piramal workers Increasing awareness about the program as well as the ill effects of steroid injections Improving the trust and reliability of Piramal eswasthya Improving confidence of people in Piramal workers 4 Key problem? Key causes that have caused the problem? 5 What might have been the ‘criteria’ used to make these ‘key decisions’ in the past? 6 Write the criteria as a standard vis-à-vis with which the decision ‘options’ can be evaluated?    7 What were the other decision options available when the key decision/option was chosen?  Make sahayika compensation linked to number of patients treated to provide incentives to reach out more Increase marketing specifically targeted at increasing awareness about Piramal and ill effects of steroid use Scrap the project completely Tie up with local institutions to increase awareness Target places frequented by rural population and key products used by them   8 What were the ‘Action Points’ that were implemented to give effect to the ‘key decision option’?    9 In retrospect do you think the ‘key decision’ was right? Did it solve the problem by addressing the right cause? Enighten people about the projects process and assure them that Piramal thinks about their well being Yes, the key decision would most suitably attack the basic problems that Piramal is facing No. B 1 Question......

Words: 957 - Pages: 4

The Stark and Harsh Reality of Media in India

...Publications has had the managing director (MD) of Pantaloon Retail, Kishore Biyani, McDonald India's MD Vikram Bakshi, and leather-maker Mirza International's MD Rashid Mirza, and also the CEO of media consulting firm Lodestar Universal India, Shashidhar Sinha, and the chairman of the real estate firm JLL Meghraj, Anuj Puri.  The board of directors of HT Media, publishers of Hindustan Times and Hindustan, has included the former chairman of Ernst & Young K. N. Memani and the chairman of ITC Ltd Y C Deveshwar.  Joint MD of Bharti Enterprise Rajan Bharti and MD of Anika International Anil Vig are a part of the TV Today's Board of Directors. The board of directors of DB Corp (that publishes Dainik Bhaskar) includes the head of Piramal Enterprises Group, Ajay Piramal, the MD of Warburg Pincus, Nitin Malhan, and the executive chairman of advertising firm Ogilvy & Mather, Piyush Pandey.  NDTV's Board of Directors has Pramod Bhasin, President & CEO of the country's biggest BPO company GenPact as a member of its board of directors. Regarding content, separate study is needed but a few points may be noted.  In the case of India, media empires have had to adjust their strategies to suit the Indian context.  The Murdoch STAR TV realized that its mainly American oriented programming was only reaching a tiny, although wealthy, urban audience.  It therefore started adding Hindi subtitles to Hollywood films broadcast on its 24-hour channel and dubbing popular U.S. soaps into......

Words: 2735 - Pages: 11

Indian Pharmaceutical Industry

...of US$12 is among the lowest in the world, similar to levels in Pakistan and Vietnam. .India accounts for almost 10% of the global market by volume and is rapidly emerging as the leading outsourcing partner of global pharmaceutical companies, strengthened by improving Research and Development (R&D) focus and strategic position in the pharmaceutical value chain. The Industry structure of Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units with severe price competition and government price control. There are about 3,000 pharmaceutical manufacturers, the vast majority of which focus on generic drugs. The major players in the industry are Ranbaxy, Cipla, Dr. Reddy's Laboratories, Lupin, Nicolas Piramal,Aurobindo Pharma, Cadila Pharmaceuticals, Sun Pharma, W Wockhardt Ltd. and Aventis Pharma. The industry encourages international interest because of the growing population and economic improvements . Furthermore, initiatives of the Government such as allowing 100% FDI under the automatic route in drugs and pharmaceuticals including those involving use of recombinant technology act as a catalyst for growth. The main regulatory body in India under the Ministry of Health and Family Welfare is Central Drugs Standard Control Organisation (CDSCO). It is responsible for ensuring safety, efficacy and quality of drugs supplied to the public....

Words: 257 - Pages: 2

Michel Fernandes at Nicholas Piramal

...CASE STUDY: MICHEL FERNANDES AT NICHOLAS PIRAMAL 1. What is at stake for the business development function and for the company as a whole? 1) Sake for Business Development Function: Due to managerial conflicts between 3 senior managers, original plan will not be fully developed or properly implanted. As a result, integration as one will collapse if three senior managers do not communicate or work as a team. 2) Stake for a Company as a Whole: Firstly the inefficient management will increase the managerial cost which leads to revenue loss and loss of future earnings growth opportunities. The weaker financial position might further lead the company losing its competitiveness in the global market. In addition, the risk for running management inefficiently in a long term will be the collapse of the whole company. The cost here will be restructuring of the whole operations. 2. Why is conflict occurring? Even at the beginning of the acquisition, the structure of the company is already unclear and complex. Three different plants were independent companies and completely separated. Firstly, cultural conflicts between different companies and also among three management seniors have become a sever barrier for effective operations and communications for the management of the company. Grundy complained that Ananth’s Indian action-oriented operational style will not fit in with English plan/do/review style. Anath’s idea “hustle” does...

Words: 1057 - Pages: 5

Itm. Piramal Healthcare

...ASSIGNMENT INTRODUCTION TO MANAGEMENT PIRAMAL HEALTHCARE LTD. [pic] INDEX SR.NO. PARTICULARS PAGE NO. 1 INTRODUCTION 3 2. VISION AND VALUES 4 3. ORGANIZATION STRUCTURE 5 4. HUMAN RESOURSCE MANAGEMENT 6 5. INNOVATION 9 6 OPERATION MANAGEMENT 11 INTRODUCTION Piramal Healthcare Ltd., a Piramal Group company, is a globally integrated healthcare company that fulfills unmet medical needs across the world. It has a growth track record of above 29% CAGR since 1988. Piramal Healthcare had consolidated revenues of THEM$ 656 million in FY2009. PHL is currently ranked 4th in the Indian market with a diverse product portfolio spanning several therapeutic areas. It is also one of the largest custom manufacturing companies with a global footprint of assets across North America, Europe and Asia. VISION AND VALUES They believe they can create value only if they care for the ones they serve, that their care will have an impact only if it is followed by timely and bold action, and that they will take timely action if it is backed by......

Words: 1217 - Pages: 5

Analysis of Indian Pharmaceutical Industry

...system of medicine has been in practice for many centuries. Therefore, in discussing the evolution of the IPI, 5 points of time are very relevant. These are: 1900-1970, 1970-1980, 1980-1990, 1990-2000, 2000 and beyond. INDUSTRY STRUCTURE Indian pharma industry is currently highly fragmented and accounts for only about 1% of the GDP. The Guinea Coefficient of the sector is 78.2%, indicating unequal distribution of market shares in the market shares of companies. Moreover, the HHI index gives a value of 387, indicating highly competitive market structure. TOP 10 PHARMA COMPANIES IN INDIA 1. Ranbaxy 2. Dr Reddy Laboratories 3. Sun Pharma 4. Cipla 5. Aurobindo Pharma 6. GlaxoSmithKline 7. Lupin 8. Piramal 9. Ipca 10. Aventis ANALYSIS AND INTERPRETTION OF THE INDIAN INDUSTRY 1. INDUSTRY LIFE CYCLE ANALYSIS Many industrial economists believe that the development of almost every industry may be analyzed in terms of the life cycle with four well-defined stages. The stages are: * Pioneering stage * Rapid growth stage * Maturity and stabilization stage * Decline stage Pioneering stage: During this stage, the technology and/or the product is relatively new. Lured by promising prospects, many entrepreneurs enter the field. As a result, there is keen and often chaotic competition. Only a few entrants may survive this stage. Most of today's major pharmaceutical companies were founded in the late......

Words: 11741 - Pages: 47

Nicholas Piramal India Limited

...This 4 page paper is based on a case study supplied by the student. Nicholas Piramal India Ltd (NPIL) has acquired Avecia. The post acquisition merger is going badly, with a clash of cultural styles. The paper assesses how and why there are problems and looks at the way the problem may be resolved. The bibliography cites 2 sources. Michael Fernandez, director of special operations in the pharmaceutical company Nicholas Piramal India Limited (NPIL), schedule a meeting with three of his reports, whose personal conflicts with each other, cause its business development function to fail. He is struggling to learn how to deal with these conflicts and combine three in productive cooperation work. Fernandez is responsible for turning NPIL acquisitions in Canada and the United Kingdom market NPIL worldwide. His three direct reports, each involved in different aspects of NPIL – Canadian operations, the British operations and global business development, and it explores the dynamics between the two teams. If Fernandes can resolve conflicts, the integration of acquisitions is in danger  2. Why is conflict occurring? Even at the beginning of the acquisition, the structure of the company is already unclear and complex. Three different plants were independent companies and completely separated. Firstly, cultural conflicts between different companies and also among three management seniors have become a sever barrier for effective operations and communications for the management of......

Words: 335 - Pages: 2

External Factors in Organaization

...enough information about products to other countries to determine if the product is marketable around the globe (Moon, 2010). Information is organized through technology; via Internet so customers are better informed regarding price, and other vital information before purchasing. 1.2.the needs and Expectations of stakeholders in orchid The board of Piramal Healthcare has approved the spin-off of the New Chemical Entity (NCE) from Piramal Life Sciences, reports CNBC-TV18. The unit will then be merged with parent. According to the company filing with BSE, shareholders will be issued one fully paid up equity share of Rs 2 of parent Piramal Healthcare for every four shares of Rs 10 held of Piramal Life Sciences. Investment in NCE research calls for sharper research focus, longer time horizon and higher risk appetite, said a press release. CNBC-TV18 had earlier reported about how Piramal Health is more poised to take the risks arising from the drug discovery business than Piramal Life Sciences. This demerger is expected to be completed in six months, Ajay Piramal was quoted as saying. Piramal hopes, ultimately, to re-absorb Piramal Life Sciences back into the company. According to CNBC-TV18, long-term strategies of the company include hiking capacity in active pharmaceutical ingredients segment and formulations business. 1.3. major changes taking place in the external environment it affects stretegy This process is most applicable to strategic management at the business......

Words: 2406 - Pages: 10

Pharmaceutical Industry in India

...of global medicine. * Procures more than 50 % revenue coming from the overseas markets through exports MAJOR PLAYERS IN THE INDUSTRY Company | Market Share (%) | Total Pharma Market | 100.0 | Cipla | 5.3 | Ranbaxy | 5.0 | Glaxo Smithkline | 4.3 | Piramal Healthcare | 3.9 | Zydus Cadila | 3.6 | Source: ORG IMS | 1. Ranbaxy Laboratories Limited * Biggest pharmaceutical manufacturing company in India * Ranked at the 8th position among the global generic pharmaceutical companies * Has presence in 48 countries including world class manufacturing facilities in 10 countries 2. Dr. Reddy's Laboratory * Has 60 active pharmaceutical ingredients to manufacture drugs, critical care products, diagnostic kits and biotechnology products * The company has 6 FDA plants that produce active pharma ingredients and 7 FDA inspected and ISO 9001 and ISO 14001 certified plants 3. Cipla * Renowned for the manufacture of low cost anti AIDS drugs * The company's product range comprises of anthelmintics, oncology, anti-bacterials, cardiovascular drugs, antibiotics, nutritional supplements, anti-ulcerants, anti-asthmatics and corticosteroids. 4. Nicholas Piramal * Second largest pharmaceutical healthcare company in India * Brands manufactured by the company include Gardenal, Ismo, Stemetil, Rejoint, Supradyn, Phensedyl and Haemaccel * Has entered into joint ventures and alliances with several international......

Words: 1006 - Pages: 5

Efefe

...TRANSFORMATIVE HR PRACTICES AT PIRAMAL GROUP- ALIGNMENT OF VALUES , HR PROCESSES AND EMPLOYEE ENGAGEMENT CHUNDURU SRINIVAS and MEENU BHATIA By MIRIYALA VENKATA SAIRAM MAYANK GOEL MIRZA ASGAR ALI About the Authors : Chunduru Srinivas : He has been with the Piramal Group for over a decade and is currently working as President – Human resources and Strategy . His areas of interest include new business opportunities ,M&A ,Investor relations ,Performance Management systems and Strategic planning. He is a regular speaker and has shared his views on skill building , challenges of learning organizations ,Employee engagement , Performance management system etc. Mentoring and teaching has been a passion and he has been addressing students since 13 years. He as been a speaker at prestigious management schools to name a few S.P.J.I.M.R , XLRI ,IIM – lucknow etc. He regularly mentors about 2500 MBA students yearly. Meenu Bhatia : She has been with piramal group since last three years and is currently managing the Learning and Development and Employee Engagement initiatives for the Piramal Group . She has spent more than 10 years in the HR domaon pursuing her passion in integrated development , content designing, Organizational development etc. Meenu is also a certified MBTI practitioner . She is also a core team member and an advisor to Umang foundations ,an NGO that......

Words: 1104 - Pages: 5

Dominos

...Yogesh Chander Deveshwar | ITC | 39 | 16 | Pawan Munjal | Hero Honda Motors | 40 | 31 | Anand Burman | Dabur | 41 | NA | Neeraj Swaroop | Standard Chartered | 42 | 84 | Naresh Goyal | Jet Airways | 43 | 20 | Kiran Mazumdar Shaw | Biocon | 44 | 28 | SP Hinduja | Hinduja Group | 45 | 59 | Shinzo Nakanishi | Maruti Suzuki India | 46 | 77 | Naveen Jindal | Jindal Steel | 47 | 36 | Jaiprakash Gaur | Jaypee Group | 48 | NA | N Chandrasekaran | TCS | 49 | NA | MA Alagappan | Murugappa Group | 50 | 46 | Nusli N Wadia | Bombay Dyeing | 51 | NA | M M Murugappan | Murugappa Group | 52 | NA | R Seshasayee | Ashok Leyland | 53 | 49 | Deepak Puri | Moser Baer | 54 | NA | Yogesh Aggarwal | IDBI | 55 | 78 | Ajay G Piramal | Piramal Enterprises | 56 | 91 | PM Telang | Tata Motors | 57 | NA | Nitin Paranjpe | Hindustan Unilever | 58 | 62 | Ratan Jindal | JSL | 59 | 60 | Venugopal N Dhoot | Videocon International | 60 | 51 | Gautam Adani | Adani Enterprise | 61 | 92 | B N Kalyani | Bharat Forge | 62 | 88 | Habil F Khorakiwala | Wockhardt | 63 | NA | PRS Oberoi | East India Hotels | 64 | 37 | Sajjan Jindal | JSW Steel | 65 | 56 | R K Krishna Kumar | Tata Sons | 66 | NA | Analjit Singh | Max India | 67 | NA | P R Menon | Tata Power | 68 | 63 | Suneel M Advani | Bluestar | 69 | NA | N Srinath | Tata Communications | 70 | NA | R S Sharma | ONGC | 71 | 54 | K M Mammen | MRF | 72 | 34 | Dilip S Shanghvi | Sun Pharmaceuticals | 73 |......

Words: 635 - Pages: 3

Financial

...research-oriented firm, preceding many of its peers in setting up a New Drug Development Research (NDDR) in 1993 and out-licensing its first compound just four years later. Dr. Reddy’s has since outlicensed two more molecules and currently has three others in clinical trials. Although Dr. Reddy’s is publicly traded, the Reddy family (including founder/chairman K. Anji Reddy, son-in-law/CEO GV Prasad and son/COO Satish Reddy) holds a hefty 26% share in the company.11,44 [edit] Nicholas Piramal The company led by Asish Mishra grossing $350 million per year, Nicholas Piramal started its existence with the 1988 acquisition of Nicholas Laboratories and grew through a series of mergers, acquisitions and alliances. The company has formed a name for itself in the field of custom manufacturing. It cites its 1700-person global sales force as another core strength; with its acquisition of Rhodia’s inhalation anaesthetics business, Nicholas Piramal gained a sales and marketing network spanning 90 countries34. Nicholas Piramal is well-poised for the challenge of surviving in the aftermath of product patent protection. The company has respected intellectual property rights since its inception and refused to "support generic companies seeking first-to-file or early-to-market strategies." Instead, it decided to make its own intellectual property and opened a research facility last November in Mumbai with hopes of launching its first drug in 2010 at a cost of $100,000.24,33 [edit]......

Words: 1204 - Pages: 5

Piramal Healthcare

...at work Annual Report 2009-10 Contents Management Discussion and Analysis ............................. 01 Directors’ Report ....................... 26 Historical Performance .............. 29 Key Performance Indicators ....... 30 Corporate Information .............. 32 Auditors’ Report ........................ 36 Balance Sheet ............................ 40 Profit and Loss Account ............. 41 Cash Flow Statement ................. 42 Statement Relating to Subsidiary Companies ................ 71 Corporate Governance ............... 72 Auditors’ Report - Consolidated ........................... 83 Consolidated Balance Sheet ....... 84 Consolidated Profit and Loss Account ...................... 85 Consolidated Cash Flow Statement ................. 86 At work The cover depicts an artist’s representation of a gyroscope. Encyclopedia Britannica says the 19th C French physicist Foucault gave the name gyroscope to a wheel or rotor mounted in gimbal rings. Such a spinning wheel maintained its original orientation in space regardless of the Earth’s rotation, which made it ideal as a direction indicator. Gyroscopes are used in compasses and automatic pilots on ships and aircraft, in the steering mechanisms of torpedoes, and in the inertial guidance systems installed in space launch vehicles, ballistic missiles, and orbiting satellites. The steadfastness of the gyroscope is quite like the philosophy we work by at Sun Pharma. Staying the course, steady and consistent,......

Words: 41744 - Pages: 167